Karma Oncology Ltd

Karma Oncology is a specialized oncology clinical development organisation headquartered in Scotland with offices in Ireland, Netherlands and USA.

Karma offers a bespoke service, from the preparation of clinical development plans through design, set-up & execution of clinical trials. Our expertise includes the design and execution of autologous and CAR-T cell therapy studies in Europe and North America.

The company was founded in 2012 by Dr Karen J Williams, who, while working as a Sponsor, had become increasingly frustrated by the inevitable constraints and rigidity smaller companies can experience being lost and forgotten in larger CRO’s. Utilizing her 30 years’ experience in pharma and CRO industries, Dr Williams started Karma Oncology to ensure smaller biotech’s get the service and attention they deserve. She has surrounded herself with like-minded professionals and built a team, who, like herself have a passion for this work and are nowledgeable, Adaptable, Reliable, Motivated and Accountable.

Dr Karen Williams

National Institute for Health Research (NIHR) Clinical Research Network

Exhibiting at booth 5b

Working in partnership with the life sciences industry

  • Access to NHS clinical expertise
  • Accurate national and local feasibility
  • Streamlined site identification
  • Study set-up support 
  • Proactive performance monitoring  
  • All free of charge

Funded by the UK government, the National Institute for Health Research (NIHR) Clinical Research Network (CRN) delivers high quality research in partnership with the UK’s National Health Service (NHS). Our Study Support Service is free of charge and helps the life sciences industry plan, set-up and deliver high quality research to time and target, across all therapeutic areas. 

We are your route to accessing the UK’s unified research system - the most integrated health research system in the world.

Natalie Wilson
Business Development Manager 
Theo Christie
Business Development Manager 
Sinead Collinge
Operations and Business Development Manager 

Precision for Medicine, Oncology and Rare Disease

Precision for Medicine, Oncology and Rare Disease is the first comprehensive, fully integrated CRO devoted to oncology and rare disease combining this unique experience with Omics, big data + biomarker-guided drug development.

Precision’s uniquely integrated offering enables the science of precision medicine by combining novel clinical trial designs, industry-leading operational and medical experts, advanced biomarker solutions, and an unequivocal passion for rare diseases and oncology. We provide an uncommon array of talent and services to enable our pharmaceutical and life sciences clients to access new advancements, stay ahead of regulatory changes and ultimately achieve their goals faster. The result: a tailored pathway to approval for oncology and rare disease innovators.

Angelique Heckmann
Director, Strategic Development, Europe